Synopsys (SNPS) reachead $533.30 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Synopsys remains a buy due to its leadership in EDA software and semiconductor IP, despite recent share price struggles and market reactions to DeepSeek's AI model. The company's strong financial performance, with 15% revenue growth and 25% EPS growth in 2024, underscores its robust business fundamentals. Upcoming earnings are expected to show declines due to a fiscal year change, but Synopsys has a history of beating guidance, suggesting potential upside.
Synopsys (SNPS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Synopsys (SNPS) closed the most recent trading day at $551.54, moving +1.26% from the previous trading session.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Synopsys (SNPS) reachead $515.81 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.
Synopsys, Inc. (NASDAQ:SNPS ) 27th Annual Needham Growth Conference January 16, 2025 11:00 AM ET Company Participants Shelagh Glaser - CFO Conference Call Participants Charles Shi - Needham & Company Charles Shi Good morning. Welcome to the 27th Annual Needham Growth Conference.
Zacks.com users have recently been watching Synopsys (SNPS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
SNPS is affected by the U.S.-China trade war and slow recovery across key business segments. Yet, its strategic collaborations and AI investments are upsides.
Companies exposed to artificial intelligence and accelerated computing have continued to see their end demand and visibility strengthen.
The European Commission (EC) has given the greenlight for Synopsys to acquire Ansys, though the companies must divest some half-a-dozen products as part of the proposed remedies.
The commission said that the companies' offer to sell two business units to a rival fully addresses its concerns.